The HER2-positive subtype, a member of the receptor tyrosine kinase family, represents about 10% of BC cases, and is characterized by the absence of ER/PR, higher HER2 expression, and is more aggressive and faster-growing than luminal cancers [3,5,7]. Here, ERBB2 is linked to breast cancer.